Prioritization schema for immunotherapy clinical trials in glioblastoma.

ABSTRACT:

Background

Emerging immunotherapeutic strategies for the treatment of glioblastoma (GBM) such as dendritic cell (DC) vaccines, heat shock proteins, peptide vaccines, and adoptive T-cell therapeutics, to name a few, have transitioned from the bench to clinical trials. With upcoming strategies and developing therapeutics, it is challenging to critically evaluate the practical, clinical potential of individual approaches and to advise patients on the most promising clinical trials.

Methods

The authors propose a system to prioritize such therapies in an organized and data-driven fashion. This schema is based on four categories of factors: antigenic target robustness, immune-activation and -effector responses, preclinical vetting, and early evidence of clinical response. Each of

SUBMITTER: Hodges TR 

PROVIDER: S-EPMC4938323 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature